Unknown

Dataset Information

0

Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study.


ABSTRACT:

Purpose

This single-arm prospective cohort study aimed to evaluate the feasibility and utility of in-home body weight support harness system (BWSS) use in children treated for spinal muscular atrophy (SMA).

Methods

Individuals with 2 or 3 copies of SMN2 who received pharmacotherapeutic treatment, had head control, and weight <50lbs were enrolled. Families were provided a BWSS and documented use. Motor outcome assessments were completed at baseline, month 3 and month 6. Families provided feedback in an end of study survey.

Results

All 32 participants (2.9 (SD 1.9) yrs), improved or remained stable on all outcomes. Average reported frequency of use was 4.1(2.3) hrs/week. Controlling for other covariates, frequency of use explained over 70% of the variability in change scores. Family feedback was overwhelmingly positive.

Conclusion

Use of in-home BWSS is a safe, feasible and useful option to increase exercise dosage after treatment in SMA and may help optimize motor abilities.

Trial registration

Study registered with: Clinicaltrials.gov Clinicaltrials.gov identifier: NCT05715749.

SUBMITTER: Iammarino MA 

PROVIDER: S-EPMC10950233 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feasibility and utility of in-home body weight support harness system use in young children treated for spinal muscular atrophy: A single-arm prospective cohort study.

Iammarino Megan A MA   Alfano Lindsay N LN   Reash Natalie F NF   Sabo Brenna B   Conroy Sara S   Noritz Garey G   Wendland Madalynn M   Lowes Linda P LP  

PloS one 20240319 3


<h4>Purpose</h4>This single-arm prospective cohort study aimed to evaluate the feasibility and utility of in-home body weight support harness system (BWSS) use in children treated for spinal muscular atrophy (SMA).<h4>Methods</h4>Individuals with 2 or 3 copies of SMN2 who received pharmacotherapeutic treatment, had head control, and weight <50lbs were enrolled. Families were provided a BWSS and documented use. Motor outcome assessments were completed at baseline, month 3 and month 6. Families pr  ...[more]

Similar Datasets

| S-EPMC8139063 | biostudies-literature
| S-EPMC4514700 | biostudies-other
| S-EPMC4613485 | biostudies-literature
| S-EPMC3164180 | biostudies-literature
| S-EPMC6138687 | biostudies-literature
| S-EPMC9878289 | biostudies-literature
| S-EPMC3110347 | biostudies-literature
| S-EPMC9503857 | biostudies-literature
| S-EPMC2527655 | biostudies-literature
| S-EPMC5802612 | biostudies-literature